VISEN Pharmaceuticals (Cayman) disclosed a fresh on-market share repurchase on 12 June 2026, trimming its issued share base and lifting treasury stock levels.

Key transaction details • Volume repurchased: 5,900 ordinary shares, equal to 0.005 % of the 113.81 million shares outstanding prior to the trade. • Price range: HKD 19.91–20.06 per share; volume-weighted average price: HKD 19.98. • Total consideration: HKD 0.12 million. • All repurchased shares are being held as treasury stock; no cancellations have been executed to date.

Capital structure impact • Issued shares (excluding treasury) fell to 113.80 million. • Treasury shares increased to 125,800, keeping total issued shares unchanged at 113.93 million.

Repurchase mandate utilisation • The current general mandate, approved on 27 June 2025, allows buybacks of up to 11.39 million shares. • Cumulative repurchases under this mandate now stand at 125,800 shares, representing 0.11 % of the authorised limit.

Regulatory window Under Hong Kong Stock Exchange rules, VISEN Pharma is restricted from issuing new shares or disposing of treasury shares until 12 July 2026—30 days after the latest buyback.

The company affirmed that the transaction complied with all applicable listing rules and regulatory requirements.